Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, LIC

Enhance.MD Expands Telehealth Division in Partnership with iThriveMD


Enhance.MD, in partnership with iThriveMD, is launching a new weight-loss telehealth division to integrate digital and in-person healthcare.

SAN DIEGO, May 1, 2024 /PRNewswire-PRWeb/ -- Enhance.MD, a leader in innovative health and wellness solutions, is proud to announce the launch of its new weight-loss telehealth division. This strategic move comes in partnership with iThriveMD, a renowned wellness clinic that provides a full suite of comprehensive health services. Together, they aim to bridge the gap between digital and in-person healthcare, providing a seamless, integrated experience for individuals seeking weight loss, longevity and wellness solutions. Both Enhance.MD and iThriveMD are led by the seasoned healthcare executive, Chloe Belle Hooton.

Enhance.MD provides telehealth-based semaglutide membership offerings as a cornerstone of its commitment to providing effective, personalized weight loss solutions.

Enhance.MD provides telehealth-based semaglutide membership offerings as a cornerstone of its commitment to providing effective, personalized weight loss solutions. Central to this offering is its comprehensive eligibility screening process, which helps to provide a personalized treatment program and build a partnership of trust with its patients. By meticulously evaluating each patient's health profile, Enhance.MD ensures that each semaglutide treatment is not only effective but also aligned with the individual's health goals and safety requirements.

With the rise of telehealth, Enhance.MD recognizes the growing demand for accessible, convenient, and effective weight loss care. Through this partnership, Enhance.MD leverages iThriveMD's extensive expertise in proven, safe solutions such as IV nutrition, hormone replacement therapy, and semaglutide weight loss treatments. "Our collaboration between iThriveMD and Enhance.MD is a significant step towards redefining the future of healthcare. It allows us to extend our reach and offer our clients the best of both worlds ? the convenience of telehealth and the assurance of in-person clinical excellence," said Chloe Belle Hooton.

iThriveMD, with its locations in San Diego, Encinitas, and Scottsdale, has established itself as a trusted partner for individuals looking to enrich their health span and unlock their full potential. "We are excited to partner with Enhance.MD to bring our proven health and wellness solutions to a wider audience through telemedicine. This partnership aligns with our mission to provide comprehensive, personalized care that meets our clients wherever they are on their health journey," said Hooton.

About Enhance.MD

Enhance.MD, headquartered in San Diego, California, was established in 2019 as a national provider of telehealth services. By the spring of 2023, Enhance.MD strengthened its focus on overall wellness by targeting weight loss by utilizing its telehealth platform to provide GLP-1s on a national scale. Enhance.MD's leadership, alongside its advanced technological infrastructure, has been at the forefront of telemedicine since 2013, facilitating the delivery of premier prescriptions and treatments directly to your doorstep.

The company offers a patient-centered semaglutide subscription and membership service that is tailored to those seeking medically supported weight management solutions. The company utilizes a proprietary screening process to provide personalized treatment programs that are designed to be effective and safe. For more information, visit www.enhance.md.

About iThriveMD

Founded in 2021, iThriveMD is dedicated to optimizing wellness and vitality through personalized medical care, cutting-edge treatments, and holistic wellness practices. With a mission to empower individuals to live their best lives, iThriveMD offers a comprehensive approach to health that addresses the root causes of illness, balances hormones, provides weight loss solutions and nutritional counseling, and offers regenerative medicine. Their expert team takes the time to understand each individual's unique health concerns and goals, providing tailored solutions that prioritize well-being. iThriveMD believes in treating the whole person, addressing physical, emotional, and lifestyle factors to help clients achieve tangible results and experience a higher quality of life. For more information, visit www.ithrivemd.com.

Media Contact

Mike Mayo, Enhance.MD, 1 1-888-299-5088, [email protected], https://enhance.md

SOURCE Enhance.MD


These press releases may also interest you

at 23:20
Full year 2023 revenue of $90.9 million compared to $99.4 million in 2022, and $90.5 million compared to $86.7 million on a normalized basis, excluding one-time COVID mandates.Q4 2023 gross profit margin1 of 39.7% was relatively flat compared to Q3...

at 23:07
On 13 May 2024, Fortune China magazine released the 2024 China ESG Impact List, and Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the list, highlighting its outstanding performance and...

at 21:03
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been selected for...

at 21:00
Bristol Myers Squibb today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment...

at 20:54
Starlight Children's Foundation CEO, Adam Garone, has been named Nonprofit Executive of the Year (Large), by the Los Angeles Business Journal. The prestigious award was presented at the annual Nonprofit and Corporate Citizenship Award luncheon held...

at 20:35
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2...



News published on and distributed by: